INDIA – Cipla, a leading pharmaceutical company, has announced a strategic partnership with CSIR-Central Drug Research Institute (CDRI) to develop an innovative ophthalmic formulation aimed at combating fungal keratitis.
This joint effort seeks to harness the collective expertise and resources of both organizations to create a safe and effective treatment for this challenging condition.
Fungal keratitis poses a significant global health concern, with approximately 1.2 million cases reported annually worldwide, particularly prevalent in tropical regions.
Agricultural workers are particularly vulnerable due to exposure to fungal pathogens from organic matter, often following ocular trauma.
Other risk factors include the use of local steroid eye drops, injury, poor personal hygiene, and regular contact lens use. Left untreated, fungal keratitis can lead to severe corneal damage and irreversible vision loss.
The formulation developed through this collaboration has shown promising results in pre-clinical studies, demonstrating faster resolution of the infection.
Cipla will now undertake the task of scaling up production, conducting necessary studies, and seeking regulatory approvals for commercialization, with a commitment to ensuring accessibility for those in need.
Dr. Radha Rangarajan, Director of CSIR-CDRI, highlighted the institute’s dedication to addressing India’s unmet clinical needs through innovative and cost-effective solutions.
The unique ophthalmic formulation of the anti-fungal drug developed by CDRI scientists represents a significant advancement in the treatment of fungal keratitis.
This partnership underscores both Cipla’s and CSIR-CDRI’s commitment to advancing healthcare through collaborative research and development initiatives.
By combining their respective strengths, they aim to bring forth a solution that not only addresses the urgent medical needs in India but also has the potential to benefit individuals worldwide affected by fungal keratitis.
Be the first to leave a comment